FVCG bleeds into Actinobac

Feb 24, 2013 • Global Corporate Venturing

The portfolio company has exclusive rights to the therapeutic use of Leukothera, which targets Leukocyte Function Antigen-1 (LFA-1) on white blood cells, through a license from the University of Medicine and Dentistry of New Jersey.

Foundation Venture Capital Group (FVCG), the corporate venturing affiliate of New Jersey Health Foundation, has invested $100,000 in Actinobac Biomed.

LEADERSHIP SOCIETY

Informing, connecting, and transforming the global corporate venture capital ecosystem.
The Global Corporate Venturing (GCV) Leadership Society’s mission is to help bridge the different strengths and ambitions of investors across industry sectors, geography, structure, and their returns.

Find out more

GCV Powerlist 2026

Nominations for the 2026 GCV Powerlist are now open. Use this form to nominate yourself or someone else.

The World of Corporate Venturing

GCV's annual report on the state of the corporate investment sector

Corporate venture building report

Data from 100+ corporate venture building programmes, including size, budgets, staffing, reporting lines and outcomes

Events

All events

About us

GCV provides the global corporate venturing community and their ecosystem partners with the information, insights and access needed to drive impactful open innovation. Across our three services - News & Analysis, Community & Events, and the GCV Institute - we create a network-rich environment for global innovation and capital to meet and thrive. At the heart of our community sits the GCV Leadership Society, providing privileged access to all our services and resources.